Roomasa Channa Raafay Sophie Saghar Bagheri Syed M Shah Jiangxia Wang Olukemi Adeyemo Akrit Sodhi Adam Wenick Howard S Ying Peter A Campochiaro
10.1016/j.ajo.2014.09.012
Am J Ophthalmol
2015 Jan;159(1):9-19.e1-2.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/25217857/
Angiogenesis Inhibitors / therapeutic use Antibodies, Monoclonal, Humanized / therapeutic use Choroidal Neovascularization / drug therapy Macular Degeneration / drug therapy Vascular Endothelial Growth Factor A / antagonists & inhibitors
Angiogenesis Inhibitors / therapeutic use Antibodies, Monoclonal, Humanized / therapeutic use Choroidal Neovascularization / drug therapy Macular Degeneration / drug therapy Vascular Endothelial Growth Factor A / antagonists & inhibitors Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Aged Aged, 80 and over Bevacizumab Disease Progression Female Humans Incidence Macula Lutea / pathology Macular Degeneration / epidemiology Macular Degeneration / pathology Male Ranibizumab Remission Induction Retrospective Studies Tomography, Optical Coherence Angiogenesis Inhibitors Antibodies, Monoclonal, Humanized Vascular Endothelial Growth Factor A Bevacizumab Ranibizumab
PMC10020832
25217857
Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes
2015